According to our (Global Info Research) latest study, the global Deutenzalutamide Soft Capsules market size was valued at US$ 30.87 million in 2025 and is forecast to a readjusted size of US$ 375 million by 2032 with a CAGR of 12.5% during review period.
Deutenzalutamide soft capsules are a novel oral androgen receptor inhibitor modified by deuteration. By specifically binding to the androgen receptor and blocking its signal transduction, they inhibit the proliferation and survival of tumor cells, and are mainly used for the treatment of metastatic castration‑resistant prostate cancer. As a deuterated improved drug based on enzalutamide, its structural optimization enhances metabolic stability, prolongs its duration of action in vivo and improves safety. Featuring favorable oral absorption and convenient administration, it provides a better‑tolerated therapeutic option for patients with advanced prostate cancer and holds important clinical value in the field of genitourinary oncology.In 2025, global Deutenzalutamide soft capsules production reached approximately 120,000 units.
Deutenzalutamide soft capsules, as the first deuterated androgen receptor inhibitor approved in China, have filled the gap in domestic innovative drugs for the targeted treatment of metastatic castration‑resistant prostate cancer. Relying on deuteration technology, they have achieved remarkable improvements in metabolic stability and safety, showing clear clinical advantages in reducing central nervous system adverse reactions and enhancing tolerability in elderly patients.
Its market positioning focuses on differentiated therapeutic needs, mainly serving patients intolerant to or with unsatisfactory efficacy from existing medications, thus forming misplaced competition with the original enzalutamide and domestic generics and avoiding fierce price wars.
With the rising incidence of prostate cancer, accelerating population aging, and official inclusion in the medical insurance catalogue in China, the drug’s market accessibility and growth potential have been greatly enhanced, making it an important force for domestic innovative drugs to replace foreign products and seize the high‑end genitourinary oncology market.
In the future, its commercialization will be promoted through the coordination of medical insurance reimbursement, hospital access, and academic promotion. Relying on its unique clinical value and status as a domestic innovative drug, it will continue to expand its share in the rapidly growing prostate cancer drug market.
This report is a detailed and comprehensive analysis for global Deutenzalutamide Soft Capsules market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Deutenzalutamide Soft Capsules market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Deutenzalutamide Soft Capsules market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Deutenzalutamide Soft Capsules market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Deutenzalutamide Soft Capsules market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Deutenzalutamide Soft Capsules
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Deutenzalutamide Soft Capsules market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hinovapharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Deutenzalutamide Soft Capsules market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
28 Capsules Per Box
112 Capsules Per Bottle
Market segment by Combined medication
Deuteroenzalutamide in combination with Androgen Synthesis Inhibitors
Deuteroenzalutamide in combination with Hormonal Antineoplastic Drugs
Market segment by Production Technology
Innovator
Generic
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Metastatic Castration-Resistant Prostate Cancer
Non-Metastatic Castration-Resistant Prostate Cancer
Metastatic Hormone-Sensitive Prostate Cancer
Others
Major players covered
Hinovapharma
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Deutenzalutamide Soft Capsules product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Deutenzalutamide Soft Capsules, with price, sales quantity, revenue, and global market share of Deutenzalutamide Soft Capsules from 2021 to 2026.
Chapter 3, the Deutenzalutamide Soft Capsules competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Deutenzalutamide Soft Capsules breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Deutenzalutamide Soft Capsules market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Deutenzalutamide Soft Capsules.
Chapter 14 and 15, to describe Deutenzalutamide Soft Capsules sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Deutenzalutamide Soft Capsules. Industry analysis & Market Report on Deutenzalutamide Soft Capsules is a syndicated market report, published as Global Deutenzalutamide Soft Capsules Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Deutenzalutamide Soft Capsules market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.